Kinder Morgan (KMI) reported its second-quarter results after the closing bell. The company’s earnings topped analyst estimates as profits jumped 50% to $0.21 per share, while revenue rose modestly by 1.8% to $3.42 billion missing the consensus. The company’s share price rose marginally in the extended hours of trading.
The company took a hit of $653 million due to impairment of assets, which resulted in $180 million loss on a GAAP basis. Of the total costs, $600 million was due to the impairment charges recorded for assets in Oklahoma.
The board declared a $0.20-per-share dividend, 60% higher than last year. Distributable cash flow (DCF), one of the key metrics to watch, came in at $0.50 per share, up 9% compared to last year and down sequentially about 11%.
The company has the largest natural gas pipeline network in the US generating stable long-term revenues. Natural Gas division saw 11% growth in adjusted earnings, which is a major earnings contributor to Kinder Morgan.
Kinder Morgan announced in May about its plans to sell the controversial and delayed Trans Mountain Pipeline project to the Canadian government. As part of the deal, the company will receive $3.5 billion and help the government in finding a potential buyer by July 22nd. The energy giant expects to close the deal later in the year, which is expected to strengthen its balance sheet.
Related: US sanctions turn death note to oil firms
Debt burden remains a concern for Kinder Morgan’s balance sheet. At the end of the second quarter, total debt (long and short-term) remained flat at $36.7 billion compared to $36.8 billion last year but reduced slightly compared to the previous quarter. Once the Trans Mountain deal is closed, the debt burden is expected to ease by $2 billion.
Kinder Morgan expects 2018 DCF to come in at $2.05 per share and EBITDA, on an adjusted basis, around $7.5 billion. It also had accounted for paying $0.80 as dividends for the year. The company now expects to beat its leverage ratio of 5.1 times for the year. In the last 12 months, the pipeline giant’s stock is down nearly 9% and in 2018 it has declined about 2%.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on